Immunotherapy in triple-negative breast cancer: A literature review and new advances.

World J Clin Oncol · 2022 · PMC8966508 · PMID 35433291

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Moreover, pembrolizumab showed a favorable trend in overall survival (OS) (HR: 0.72, 95%CI: 0.51-1.02).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.